Roivant Sciences Ltd. (NASDAQ:ROIV) Position Reduced by Yousif Capital Management LLC

Yousif Capital Management LLC cut its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 4.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 148,891 shares of the company’s stock after selling 7,341 shares during the quarter. Yousif Capital Management LLC’s holdings in Roivant Sciences were worth $1,502,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Thompson Siegel & Walmsley LLC lifted its position in shares of Roivant Sciences by 10.1% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company’s stock worth $6,688,000 after purchasing an additional 51,705 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after purchasing an additional 1,948 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Roivant Sciences in the fourth quarter worth approximately $995,000. Monimus Capital Management LP purchased a new stake in shares of Roivant Sciences in the fourth quarter worth approximately $1,621,000. Finally, Bank of Montreal Can lifted its position in shares of Roivant Sciences by 20.2% in the fourth quarter. Bank of Montreal Can now owns 48,026 shares of the company’s stock worth $568,000 after purchasing an additional 8,084 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on ROIV. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, May 28th.

Roivant Sciences Stock Performance

Shares of ROIV opened at $11.08 on Tuesday. The firm has a market cap of $7.53 billion, a PE ratio of -73.86 and a beta of 1.16. The firm’s 50 day moving average price is $10.85 and its 200 day moving average price is $10.95. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The business had revenue of $7.57 million for the quarter, compared to the consensus estimate of $62.17 million. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. During the same period in the previous year, the business posted ($0.23) EPS. On average, sell-side analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 547,430 shares of the stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $11.34, for a total transaction of $6,207,856.20. Following the transaction, the insider now owns 38,627,181 shares in the company, valued at $438,032,232.54. This trade represents a 1.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Eric Venker sold 434,478 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the transaction, the chief operating officer now owns 1,127,290 shares in the company, valued at approximately $12,197,277.80. This trade represents a 27.82% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,972,189 shares of company stock valued at $33,059,785. 7.90% of the stock is currently owned by corporate insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.